Ascendis Pharma A/S (NASDAQ:ASND) Earns “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report released on Monday morning, Benzinga reports. They currently have a $170.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Ascendis Pharma A/S’s FY2024 earnings at ($6.54) EPS.

Several other equities analysts also recently commented on ASND. Citigroup dropped their target price on Ascendis Pharma A/S from $193.00 to $178.00 and set a buy rating for the company in a research report on Wednesday, September 4th. Stifel Nicolaus assumed coverage on shares of Ascendis Pharma A/S in a report on Friday, May 31st. They issued a buy rating and a $200.00 price objective for the company. Wells Fargo & Company reduced their target price on shares of Ascendis Pharma A/S from $277.00 to $264.00 and set an overweight rating on the stock in a report on Wednesday, September 4th. JPMorgan Chase & Co. decreased their price target on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an overweight rating for the company in a research report on Wednesday, September 4th. Finally, Jefferies Financial Group lifted their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a buy rating in a report on Tuesday, August 13th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $193.77.

Ascendis Pharma A/S Stock Up 1.6 %

NASDAQ:ASND opened at $148.88 on Monday. Ascendis Pharma A/S has a twelve month low of $85.29 and a twelve month high of $161.00. The stock’s 50-day simple moving average is $132.71 and its 200 day simple moving average is $136.43. The firm has a market capitalization of $8.67 billion, a PE ratio of -15.22 and a beta of 0.63.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Private Ocean LLC bought a new position in shares of Ascendis Pharma A/S during the 1st quarter worth approximately $36,000. Quadrant Capital Group LLC boosted its holdings in shares of Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after buying an additional 151 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 91 shares during the period. GAMMA Investing LLC grew its position in shares of Ascendis Pharma A/S by 52.0% during the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 102 shares during the period. Finally, Barometer Capital Management Inc. purchased a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $126,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.